In Vitro and in Vivo Effects of Nitrofurantoin on Experimental Toxoplasmosis
The Korean Journal of Parasitology
; : 155-161, 2016.
Article
ي En
| WPRIM
| ID: wpr-57436
المكتبة المسؤولة:
WPRO
ABSTRACT
Toxoplasma gondii is an important opportunistic pathogen that causes toxoplasmosis, which has very few therapeutic treatment options. The most effective therapy is a combination of pyrimethamine and sulfadiazine; however, their utility is limited because of drug toxicity and serious side effects. For these reasons, new drugs with lower toxicity are urgently needed. In this study, the compound, (Z)-1-[(5-nitrofuran-2-yl)methyleneamino]-imidazolidine-2,4-dione (nitrofurantoin), showed anti-T. gondii effects in vitro and in vivo. In HeLa cells, the selectivity of nitrofurantoin was 2.3, which was greater than that of pyrimethamine (0.9). In T. gondii-infected female ICR mice, the inhibition rate of T. gondii growth in the peritoneal cavity was 44.7% compared to the negative control group after 4-day treatment with 100 mg/kg of nitrofurantoin. In addition, hematology indicators showed that T. gondii infection-induced serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, biochemical parameters involved in liver injury, were reduced by nitrofurantoin significantly. Moreover, nitrofurantoin exerted significant effects on the index of antioxidant status, i.e., malondialdehyde (MDA) and glutathione (GSH). The nitrofurantoin-treated group inhibited the T. gondii-induced MDA levels while alleviating the decrease in GSH levels. Thus, nitrofurantoin is a potential anti-T. gondii candidate for clinical application.
Key words
النص الكامل:
1
الفهرس:
WPRIM
الموضوع الرئيسي:
Peritoneal Cavity
/
Pyrimethamine
/
Aspartate Aminotransferases
/
Sulfadiazine
/
Toxoplasma
/
HeLa Cells
/
Toxoplasmosis
/
Alanine Transaminase
/
Drug-Related Side Effects and Adverse Reactions
/
Glutathione
المحددات:
Animals
/
Female
/
Humans
اللغة:
En
مجلة:
The Korean Journal of Parasitology
السنة:
2016
نوع:
Article